DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for language impairment — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLanguage impairment maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for language impairment is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein phosphatase 2 catalytic subunit alpha (PPP2CA) — PPP2CA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet mlidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4I5L · 2.43 Å · ligand MALONATE ION (MLI). Experimental structure, not a prediction.
What the evidence adds up to
A 1986 study of four patients with pervasive developmental disorder, a tic disorder, and language impairment reported that haloperidol treatment for tics was followed by marked language improvement. The patients averaged three months of language gain for each week of speech therapy after starting haloperidol, whereas progress in speech therapy had been extremely slow in the years before the drug. The authors hypothesised that tic disorders in individuals with pervasive developmental disorder may mark a more positive response to dopamine antagonists like haloperidol. No language disorder had previously been described in the literature with such a predictable and marked response to pharmacological treatment, but the sample size is four patients and the condition is not specific language impairment.
Genetic studies have identified variants in four genes associated with spoken language disorders: FOXP2 and CNTNAP2 on chromosome 7, and ATP2C2 and CMIP on chromosome 16. Specific language impairment is defined as an unexpected and persistent impairment in language ability despite adequate opportunity and intelligence, with no explanatory medical conditions. It affects between 5% and 8% of pre-school children and is highly heritable. Characterisation of these genes and their pathways may enhance understanding of language disorders, but no drug treatment for specific language impairment itself is described in these abstracts.
A 2012 paper stresses the importance of diagnosis and intervention for specific language impairment but describes no pharmacological treatment. Symptoms include impairment in morphological-syntactical, lexical-semantic or pragmatic language areas, as well as non-language difficulties in motor skills, emotionality, cognitive functions, and hearing perception. Lower functional literacy, difficulty understanding spoken and written speech, and dysgrammatism in expressive language can persist and disadvantage education and employment.
What is still missing is any randomised controlled trial of a drug for specific language impairment, any replication of the haloperidol finding in a larger sample, and any evidence that genetic findings have been translated into a treatment. No drug has been tested in a controlled design for the core language deficit in specific language impairment, and patient stratification by genetic subtype or by the presence of tic disorders has not been attempted in a trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Genome Medicine · 2010 · 101 citations · open access
Recent advances in the genetics of language impairment
AbstractSpecific language impairment (SLI) is defined as an unexpected and persistent impairment in language ability despite adequate opportunity and intelligence and in the absence of any explanatory medical conditions. This condition is highly heritable and affects between 5% and 8% of pre-school children. Over the past few years, investigations have begun to uncover genetic factors that may contribute to susceptibility to language impairment. So far, variants in four specific genes have been associated with spoken language disorders - forkhead box P2 (FOXP2) and contactin-associated protein-like 2 (CNTNAP2) on chromosome7 and calcium-transporting ATPase 2C2 (ATP2C2) and c-MAF inducing protein (CMIP) on chromosome 16. Here, we describe the different ways in which these genes were identified as candidates for language impairment. We discuss how characterization of these genes, and the pathways in which they are involved, may enhance our understanding of language disorders and improve our understanding of the biological foundations of language acquisition.
A Treatable Language Disorder: Pharmacological Treatment of Pervasive Developmental Disorder
AbstractResults of treatment of four patients are described. All of the patients had pervasive developmental disorder (PDD), a tic disorder, and a characteristic pattern of speech and language impairment. The patients were treated with haloperidol for their tic disorders, and concomitant with the reduction of the frequency and severity of tics was marked improvement in language. The patients averaged 3 months of language gain for each week of speech therapy directly after the initiation of haloperidol treatment for tics. Progress in speech and language therapy was extremely slow during the years prior to treatment with haloperidol. To the authors' knowledge, no language disorder has been described in the literature which shows such a predictable and marked response to pharmacological treatment. The authors hypothesize that tic disorders in individuals with PDD may be a marker for a more positive response to dopamine antagonists like haloperidol.
Procedia - Social and Behavioral Sciences · 2012 · 2 citations · open access
The Impact of the Symptoms of Specific Language Impairment on Contemporary Education and Counseling – the Necessity of Speech and Language Therapy Approach at Schools
AbstractThe authors would like to stress the importance of diagnosis and intervention of the specific language impairment (SLI). The symptoms of SLI vary and occur in the language-related areas, from specific impairment in language areas (mostly morphological-syntactical, lexical-semantic or pragmatic) to non-language - e.g. motor skills, graphomotor skills, emotionality and adaptability, cognitive functions (memory, perception, in particular hearing perception, attention and cogitation). Lower functional literacy, difficulties in understanding of spoken and written forms of speech, dysgrammatism in expressive language, are typical symptoms, which may persist and become a disadvantage for successful education or success in choosing or maintaining a job.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
